Floatz logo

Capecitabine

Migraine Headache

Ohio UniversitySmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Migraine Headache cohort.

Asset / SponsorPhaseRating
NADOLOL
Ohio University
Phase 4BBB
Namenda
Universidad Autonoma de San Luis Potosí
Phase 3BB
PROPOFOL
University of Texas Southwestern Medical Center
Phase 2/3B
TEONANACATL
Yale University
Phase 1B
Sra-333
Eisai Inc.
Phase 2B

View all 13 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →